VERA Stock — Vera Therapeutics, Inc.

Vera Therapeutics, Inc. (VERA)

Updated October 16, 2026.

VERA is a Stock. Total return is 354.7% over the past 41.1 years.

Vera Therapeutics is a clinical-stage biotechnology company developing treatments for immunological diseases, including atacicept for immunoglobulin A nephropathy and other autoimmune kidney conditions, MAU868 for BK viremia infections, and VT-109 for B cell-mediated autoimmune diseases. As a pre-revenue development-stage company, it does not currently distribute to shareholders. This security appeals to investors with high risk tolerance seeking exposure to early-stage biotech development rather than income generation.

VERA performance

Price and return data through 2026-10-16.

Total return is 354.7% over the past 41.1 years. Over the past year its total return — price change plus distributions reinvested — is -8.6%. Its deepest 1-year drawdown was 52.0%.

VERA key facts

Asset type

Stock

Asset class

Equity

Inception date

08/28/1985

Distribution frequency

Semi-Annual

Last close

$27.88 (as of 2026-10-16)

Market cap

$2,009,125,780

Average volume

1294215.0

Dividend

$0.02

Beta

1.052

Payout ratio

0.0%

EPS

$-6.33

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

VERA risks and drawbacks

Payments are semi-annual, so cash flow is lumpy versus a monthly fund. The deepest 1-year drawdown on record here is 52.0%.

Who may consider VERA — and who may not

It is a weaker fit for investors who need monthly cash flow (VERA pays semi-annual). This is educational context, not a recommendation to buy or sell.

More on VERA

• All tickers starting with V

Tagged: Healthcare, Dividend.

Frequently asked questions